B-intervention	0	11	Trastuzumab
O	12	21	decreases
O	22	25	the
O	26	35	incidence
O	36	38	of
B-condition	39	47	clinical
I-condition	48	56	relapses
O	57	59	in
O	60	68	patients
O	69	73	with
O	74	79	early
O	80	86	breast
O	87	93	cancer
O	94	104	presenting
O	105	117	chemotherapy
O	117	118	-
O	118	127	resistant
O	128	130	CK
O	130	131	-
O	131	137	19mRNA
O	137	138	-
O	138	146	positive
O	147	158	circulating
O	159	164	tumor
O	165	170	cells
O	170	171	:
O	172	179	results
O	180	182	of
O	183	184	a
O	185	195	randomized
O	196	201	phase
O	202	204	II
O	205	210	study
O	210	211	.

O	212	217	Since
O	218	221	the
O	222	231	detection
O	232	234	of
O	235	246	circulating
O	247	252	tumor
O	253	258	cells
O	259	260	(
O	260	264	CTCs
O	264	265	)
O	266	271	which
O	272	279	express
O	280	284	HER2
O	285	287	is
O	288	290	an
O	291	298	adverse
O	299	309	prognostic
O	310	316	factor
O	317	319	in
O	320	325	early
O	326	332	breast
O	333	339	cancer
O	340	348	patients
O	348	349	,
O	350	352	we
O	353	365	investigated
O	366	369	the
O	370	376	effect
O	377	379	of
O	380	391	trastuzumab
O	392	394	on
O	395	403	patients
O	403	404	'
O	405	413	clinical
O	414	421	outcome
O	421	422	.

B-total-participants	423	430	Seventy
I-total-participants	431	435	five
B-eligibility	436	441	women
I-eligibility	442	446	with
I-eligibility	447	451	HER2
I-eligibility	452	453	(
I-eligibility	453	454	-
I-eligibility	454	455	)
I-eligibility	456	462	breast
I-eligibility	463	469	cancer
I-eligibility	470	473	and
I-eligibility	474	484	detectable
I-eligibility	485	489	CK19
I-eligibility	490	494	mRNA
I-eligibility	494	495	-
I-eligibility	495	503	positive
I-eligibility	504	508	CTCs
I-eligibility	509	515	before
I-eligibility	516	519	and
I-eligibility	520	525	after
I-eligibility	526	534	adjuvant
I-eligibility	535	547	chemotherapy
O	547	548	,
O	549	553	were
O	554	564	randomized
O	565	567	to
O	568	575	receive
O	576	582	either
O	583	594	trastuzumab
O	595	596	(
O	596	597	n
O	597	598	=
B-intervention-participants	598	600	36
O	600	601	)
O	602	604	or
B-control	605	616	observation
O	617	618	(
O	618	619	n
O	619	620	=
B-control-participants	620	622	39
O	622	623	)
O	623	624	.

O	625	629	CK19
O	630	634	mRNA
O	634	635	-
O	635	643	positive
O	644	648	CTCs
O	649	653	were
O	654	662	detected
O	663	665	by
O	666	668	RT
O	668	669	-
O	669	672	PCR
O	673	676	and
O	677	683	double
O	684	691	stained
O	692	694	CK
O	694	695	(
O	695	696	+
O	696	697	)
O	697	698	/
O	698	702	HER2
O	702	703	(
O	703	704	+
O	704	705	)
O	706	711	cells
O	712	714	by
O	715	733	immunofluorescence
O	733	734	.

O	735	738	The
O	739	746	primary
O	747	755	endpoint
O	756	759	was
O	760	763	the
B-outcome-Measure	764	765	3
I-outcome-Measure	765	766	-
I-outcome-Measure	766	770	year
I-outcome-Measure	771	778	disease
I-outcome-Measure	778	779	-
I-outcome-Measure	779	783	free
I-outcome-Measure	784	792	survival
I-outcome-Measure	793	797	rate
O	797	798	.

O	799	804	Fifty
O	804	805	-
O	805	808	one
O	809	810	(
O	810	812	89
O	812	813	%
O	813	814	)
O	815	817	of
O	818	821	the
O	822	824	57
O	825	833	analyzed
O	834	842	patients
O	843	846	had
O	847	851	HER2
O	851	852	-
O	852	862	expressing
O	863	867	CTCs
O	867	868	.

O	869	874	After
O	875	886	trastuzumab
O	887	901	administration
O	901	902	,
B-iv-bin-abs	903	905	27
O	906	908	of
B-intervention-participants	909	911	36
O	912	913	(
B-iv-bin-percent	913	915	75
I-iv-bin-percent	915	916	%
O	916	917	)
O	918	923	women
B-outcome	924	930	became
I-outcome	931	935	CK19
I-outcome	936	940	mRNA
I-outcome	940	941	-
I-outcome	941	949	negative
O	950	958	compared
O	959	961	to
B-cv-bin-abs	962	967	seven
O	968	970	of
B-control-participants	971	973	39
O	974	975	(
B-cv-bin-percent	975	977	17
I-cv-bin-percent	977	978	.
I-cv-bin-percent	978	979	9
I-cv-bin-percent	979	980	%
O	980	981	)
O	982	984	in
O	985	988	the
O	989	1000	observation
O	1001	1004	arm
O	1005	1006	(
O	1006	1007	p
O	1007	1008	=
O	1008	1009	0
O	1009	1010	.
O	1010	1013	001
O	1013	1014	)
O	1014	1015	.

O	1016	1021	After
O	1022	1023	a
O	1024	1030	median
O	1031	1037	follow
O	1038	1040	up
O	1041	1045	time
O	1046	1048	of
O	1049	1051	67
O	1051	1052	.
O	1052	1053	2
O	1054	1060	months
O	1060	1061	,
B-iv-bin-abs	1062	1066	four
O	1067	1068	(
B-iv-bin-percent	1068	1070	11
I-iv-bin-percent	1070	1071	%
O	1071	1072	)
O	1073	1076	and
B-cv-bin-abs	1077	1079	15
O	1080	1081	(
B-cv-bin-percent	1081	1083	38
I-cv-bin-percent	1083	1084	%
O	1084	1085	)
B-outcome	1086	1094	relapses
O	1095	1099	were
O	1100	1108	observed
O	1109	1111	in
O	1112	1115	the
O	1116	1127	trastuzumab
O	1128	1131	and
O	1132	1143	observation
O	1144	1147	arm
O	1147	1148	,
O	1149	1161	respectively
O	1162	1163	(
O	1163	1164	p
O	1164	1165	=
O	1165	1166	0
O	1166	1167	.
O	1167	1170	008
O	1170	1171	)
O	1171	1172	;
O	1173	1181	subgroup
O	1182	1190	analysis
O	1191	1200	indicated
O	1201	1205	that
O	1206	1210	this
O	1211	1217	effect
O	1218	1221	was
O	1222	1228	mainly
O	1229	1237	confined
O	1238	1240	to
O	1241	1246	women
O	1247	1251	with
O	1252	1253	>
O	1253	1254	3
O	1255	1263	involved
O	1264	1272	axillary
O	1273	1278	lymph
O	1279	1284	nodes
O	1285	1286	(
O	1286	1287	p
O	1287	1288	=
O	1288	1289	0
O	1289	1290	.
O	1290	1293	004
O	1293	1294	)
O	1294	1295	.

O	1296	1299	The
B-outcome	1300	1306	median
I-outcome	1307	1310	DFS
O	1311	1314	was
O	1315	1319	also
O	1320	1333	significantly
O	1334	1340	higher
O	1341	1344	for
O	1345	1348	the
O	1349	1360	trastuzumab
O	1360	1361	-
O	1361	1368	treated
O	1369	1377	patients
O	1378	1379	(
O	1379	1380	p
O	1380	1381	=
O	1381	1382	0
O	1382	1383	.
O	1383	1386	008
O	1386	1387	)
O	1387	1388	.

O	1389	1403	Administration
O	1404	1406	of
O	1407	1418	trastuzumab
O	1419	1422	can
O	1423	1432	eliminate
O	1433	1445	chemotherapy
O	1445	1446	-
O	1446	1455	resistant
O	1456	1460	CK19
O	1461	1465	mRNA
O	1465	1466	-
O	1466	1474	positive
O	1475	1479	CTCs
O	1479	1480	,
O	1481	1487	reduce
O	1488	1491	the
O	1492	1496	risk
O	1497	1499	of
O	1500	1507	disease
O	1508	1518	recurrence
O	1519	1522	and
O	1523	1530	prolong
O	1531	1534	the
O	1535	1538	DFS
O	1538	1539	.
